| EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness E Sánchez-Tilló, Y Liu, O de Barrios, L Siles, L Fanlo, M Cuatrecasas, ... Cellular and molecular life sciences 69, 3429-3456, 2012 | 584 | 2012 |
| β-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness E Sánchez-Tilló, O de Barrios, L Siles, M Cuatrecasas, A Castells, ... Proceedings of the National Academy of Sciences 108 (48), 19204-19209, 2011 | 457 | 2011 |
| Expanding roles of ZEB factors in tumorigenesis and tumor progression E Sánchez-Tilló, L Siles, O De Barrios, M Cuatrecasas, EC Vaquero, ... American journal of cancer research 1 (7), 897, 2011 | 208 | 2011 |
| The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma E Sanchez-Tillo, L Fanlo, L Siles, S Montes-Moreno, A Moros, ... Cell Death & Differentiation 21 (2), 247-257, 2014 | 126 | 2014 |
| ZEB1 Promotes invasiveness of colorectal carcinoma cells through the opposing regulation of uPA and PAI-1 E Sánchez-Tilló, O de Barrios, L Siles, PG Amendola, DS Darling, ... Clinical cancer research 19 (5), 1071-1082, 2013 | 73 | 2013 |
| ZEB1 imposes a temporary stage-dependent inhibition of muscle gene expression and differentiation via CtBP-mediated transcriptional repression L Siles, E Sánchez-Tilló, JW Lim, DS Darling, KL Kroll, A Postigo Molecular and cellular biology, 2013 | 54 | 2013 |
| ZEB1-induced tumourigenesis requires senescence inhibition via activation of DKK1/mutant p53/Mdm2/CtBP and repression of macroH2A1 O De Barrios, B Győrffy, MJ Fernández-Aceńero, E Sánchez-Tilló, ... Gut 66 (4), 666-682, 2017 | 47 | 2017 |
| ZEB1 protects skeletal muscle from damage and is required for its regeneration L Siles, C Ninfali, M Cortés, DS Darling, A Postigo Nature Communications 10 (1), 1364, 2019 | 46 | 2019 |
| ZEB1 promotes inflammation and progression towards inflammation-driven carcinoma through repression of the DNA repair glycosylase MPG in epithelial cells O de Barrios, L Sanchez-Moral, M Cortés, C Ninfali, N Profitós-Pelejŕ, ... Gut 68 (12), 2129-2141, 2019 | 37 | 2019 |
| Regulation of muscle atrophy-related genes by the opposing transcriptional activities of ZEB1/CtBP and FOXO3 C Ninfali, L Siles, DS Darling, A Postigo Nucleic Acids Research 46 (20), 10697-10708, 2018 | 36 | 2018 |
| Mitotic polarization of transcription factors during asymmetric division establishes fate of forming cancer cells Y Liu, L Siles, X Lu, KC Dean, M Cuatrecasas, A Postigo, DC Dean Nature communications 9 (1), 2424, 2018 | 21 | 2018 |
| Efficient correction of ABCA4 variants by CRISPR-Cas9 in hiPSCs derived from Stargardt disease patients L Siles, S Ruiz-Nogales, A Navinés-Ferrer, P Méndez-Vendrell, ... Molecular Therapy-Nucleic Acids 32, 64-79, 2023 | 4 | 2023 |
| The EMT factor ZEB1 paradoxically inhibits EMT in BRAF-mutant carcinomas E Sánchez-Tilló, L Pedrosa, I Vila, Y Chen, B Győrffy, L Sánchez-Moral, ... JCI insight 8 (20), 2023 | 3 | 2023 |
| High-efficiency CRISPR/Cas9-mediated correction of a homozygous mutation in achromatopsia-patient-derived iPSCs L Siles, P Gaudó, E Pomares International Journal of Molecular Sciences 24 (4), 3655, 2023 | 2 | 2023 |
| The mesodermal and myogenic specification of hESCs depend on ZEB1 and are inhibited by ZEB2 C Ninfali, L Siles, A Esteve-Codina, A Postigo Cell Reports 42 (10), 2023 | 1 | 2023 |
| Epigenetically distinct sister chromatids and asymmetric generation of tumor initiating cells Y Liu, L Siles, A Postigo, DC Dean Cell Cycle 17 (18), 2221-2229, 2018 | 1 | 2018 |
| Gene editing for inherited retinal dystrophies: precise correction of pathogenic variants and optimization of the assay design L Siles, S Ruiz-Nogales, P Mendez, P Gaudo, A Navines-Ferrer, ... EUROPEAN JOURNAL OF HUMAN GENETICS 32, 306-307, 2024 | | 2024 |
| 3 different iPSC-derived cell models for the study of Stargardt Disease and Retinitis Pigmentosa A Navines-Ferrer, P Mendez, L Siles, P Gaudo, E Pomares EUROPEAN JOURNAL OF HUMAN GENETICS 32, 113-114, 2024 | | 2024 |
| Three iPSC-derived cell models for the study of Stargardt Disease and Retinitis Pigmentosa. AN Ferrer, PM Vendrell, L Siles, PG Pardo, E Pomares Investigative Ophthalmology & Visual Science 64 (8), 5070-5070, 2023 | | 2023 |
| Generation of retinal models from two iPSC lines derived from patients harboring mutations in PDE6A and PDE6C genes. PG Pardo, A Navinés-Ferrer, PM Vendrell, L Siles, E Pomares Investigative Ophthalmology & Visual Science 64 (8), 3195-3195, 2023 | | 2023 |
